Gallium-68-DOTA-minigastrin - Novartis
Alternative Names: 68Ga-DOTA-MGS5; 68Ga-labelled [DOTA0,DGlu1,desGlu2-6,(N-Me)Nle11,1-Nal13]minigastrin; 68Ga-labelled minigastrin analogue; Gallium-68-DOTA-MGS5Latest Information Update: 15 Dec 2023
At a glance
- Originator Novartis
- Class Antineoplastics; Imaging agents; Organometallic compounds; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Neuroendocrine tumours
Most Recent Events
- 30 Jun 2023 Novartis in collaboration with Medical University Innsbruck completes a phase I/II trial in Neuroendocrine tumours (Diagnosis) in Austria (IV) (NCT06155994)
- 16 Jun 2021 Pharmacodynamics data from a preclinical trial in Neuroendocrine tumours released by Medical University of Innsbruck
- 20 Jan 2021 Phase-I/II clinical trials in Neuroendocrine tumours (Diagnosis) in Austria (IV) (NCT06155994)